Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Long-term prophylaxis
17 evidence topics · 17 sources
First-line long-term prophylaxis options: guideline recommendations
Subcutaneous plasma-derived C1 inhibitor: indication and dosing
Intravenous plasma-derived C1 inhibitor: indication and dosing
Lanadelumab: indication and dosing interval
Berotralstat: oral prophylaxis and dosing
Garadacimab: mechanism, population, and dosing
Donidalorsen: indication, mechanism, and dosing
Lanadelumab and berotralstat: guideline summary of efficacy
“Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be aware of delayed onset of action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attenuated androgens: second-line prophylaxis
“We recommend the use of androgens only as second-line long-term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant extended-release tablet for prophylaxis: CHAPTER-3 phase 3 results (investigational)
Attacks during prophylaxis and continued access to on-demand treatment: guideline statements
“Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients have access to ODT, even while receiving LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attacks and on-demand treatment use during prophylaxis: systematic review of 45 studies
“Forty-five primary studies met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60 IU/kg twice weekly at 16 weeks, and 44% for lanadelumab 300 mg every second week at 6 months (77% during steady-state [days 70–182]); there was no difference in attack-free rate for berotralstat 150 mg versus placebo at 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence, switching, and on-demand use after starting prophylaxis: US claims
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand prescriptions after starting subcutaneous prophylaxis: US claims
“Study population included 196 patients (C1-INH-SC: N=65; lanadelumab: N=131); mean age was 39 years and 69% were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized number of ODT prescriptions was 3.8 (3.6–4.1) per patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand rescue medication during intravenous C1 inhibitor prophylaxis: US claims
“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand dispensing during lanadelumab or berotralstat prophylaxis: Swedish national register
“Among patients with ≥12 months on modern LTP (n=69) who had at least one ODT dispensation event during their most recent 12 months of treatment (n=46/59 for lanadelumab; n=8/9 for berotralstat), the mean number of ODT packages dispensed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in addition to emergency stock ODT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“was 4.3 per patient on lanadelumab and 6.5 per patient on berotralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 22% (n=15/69) of patients receiving modern LTP did not dispense ODT medication during their most recent 12-months of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Breakthrough attack rate during prophylaxis: KONFIDENT-S interim analysis
“As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote